Page 21 - Haematologica3
P. 21
Editorials
2. Egeberg O. Changes in the activity of antihemophilic a factor (f. Viii) and in the bleeding time associated with muscular exercise and adrenalin infusion. Scand J Clin Lab Invest. 1963;15:539-549.
3. Cash JD, Gader AM, da CJ. Proceedings: The release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-d-arginine vasopressin, angiotensin and oxytocin in man. Br J Haematol. 1974;27(2):363-364.
4. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol. 1975;30(1):81-93.
5. Richardson DW, Robinson AG. Desmopressin. Ann Intern Med. 1985;103(2):228-239.
6. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d- arginine vasopressin: a new pharmacological approach to the man- agement of haemophilia and von Willebrands' diseases. Lancet. 1977;1(8017):869-872.
7. Warrier AI, Lusher JM. DDAVP: a useful alternative to blood compo- nents in moderate hemophilia A and von Willebrand disease. J Pediatr. 1983;102(2):228-233.
8. Mariani G, Ciavarella N, Mazzucconi MG, et al. Evaluation of the effectiveness of DDAVP in surgery and bleeding episodes in hemo- philia and von Willebrand's disease. A study of 43 pateints. ClinLab Haematol 1984;6:229
9. de la Fuente B, Kasper CK, Rickles FR, Hoyer LW. Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin. Ann Intern Med. 1985;103(1):6-14.
10. Mannucci PM, Ghirardini A. Desmopressin: twenty years after. Thromb Haemost. 1997;78:958.
11. Loomans JI, Kruip MJHA, Carcao M, J et al, for the RISE consortium. Desmopressin in moderate hemophilia A patients: a treatment worth considering. Haematologica 2018;103(3):550-557.
12. Revel-Vilk S, Blanchette VS, Sparling C, Stain AM, Carcao MD. DDAVP challenge tests in boys with mild/moderate haemophilia A. Br J Haematol. 2002;117(4):947-951.
13. Stoof SCM, Sanders YV, Cnossen MH, de Maat MPM, Leebeek FWG, Kruip MJHA. Desmopressin response in hemophilia A patients with FVIII: C < 0.10 IU mL-1. J Thromb Haemost 2014;12(1):110-112.
14. Oldenburg J. Optimal treatment strategies for hemophilia: achieve- ments and limitations of current prophylactic regimens. Blood 2015; 125(13):2038-44.
15. Eckhardt CL, Van Velzen AS, Peters M, et al. for the INSIGHT study group. Factor VIII gene (F8) mutation and risk of inhibitor develop- ment in nonsevere hemophilia A. Blood. 2013;122(11):1954–1962.
haematologica | 2018; 103(3)
381
